Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those pretreated with GnRH antagonist compared to those not pretreated with GnRH antagonist.

NCT Number	NCT06375811
Lead Sponsor	Yale University Collaborators: University of Colorado, Denver, Northwestern University, University of North Carolina, Duke University, Johns Hopkins University
Conditions	Infertility, Endometriosis
Enrollment	97 participants
Start Date	2024-03-16
Primary Completion	2027-03-31 (estimated)
Study Completion	2027-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-05